Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1

Suspended

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia in Remission
Recurrent Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome With Excess Blasts
Chronic Myelomonocytic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Bone Marrow Transplantation
Drug: Mycophenolate Mofetil
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Fludarabine Phosphate
Drug: Tacrolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2018-09-14

Last Posted Date: 2024-05-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03670966

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Phase 1

Recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma

Interventions: Biological: Azer-cel
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2018-09-11

Last Posted Date: 2024-12-16

Lead Sponsor: Imugene Limited

Target Recruit Count: 129

Registration Number: NCT03666000

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 18 locations

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Recurrence Tumor
Metastatic Cancer
Solid Tumor

Interventions: Biological: TIL
Drug: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-09-05

Last Posted Date: 2024-08-13

Lead Sponsor: Tongji Hospital

Target Recruit Count: 40

Registration Number: NCT03658785

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Hepatocellular Carcinoma
Refractory Liver Carcinoma
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8

Interventions: Drug: Cyclophosphamide
Biological: Cytokine-based Biologic Agent IRX-2
Biological: Nivolumab

First Posted Date: 2018-08-31

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 8

Registration Number: NCT03655002

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Phase 2

Conditions: Hematopoietic System--Cancer

Interventions: Drug: Cyclophosphamide

First Posted Date: 2018-08-31

Last Posted Date: 2018-08-31

Lead Sponsor: Capital Research Institute of Pediatrics

Target Recruit Count: 100

Registration Number: NCT03654703

Locations: 🇨🇳
Yan Yue, Beijing, Chaoyang District, China

Liver Transplantation With Tregs at UCSF

Phase 1

Terminated

Conditions: Liver Transplant

Interventions: Biological: arTreg
Procedure: leukapheresis
Drug: cyclophosphamide
Drug: mesna
Drug: everolimus

First Posted Date: 2018-08-31

Last Posted Date: 2024-04-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT03654040

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Phase 1

Withdrawn

Conditions: Chordoma
Unresectable Malignant Neoplasm

Interventions: Biological: Aldoxorubicin Hydrochloride
Radiation: SBRT
Biological: ALT-803
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-6301
Biological: haNK
Drug: Avelumab
Drug: Cetuximab
Drug: Cyclophosphamide

First Posted Date: 2018-08-27

Last Posted Date: 2021-03-19

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03647423

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Phase 3

Recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Interventions: Drug: Bortezomib
Drug: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Dexamethasone
Drug: Myocet
Drug: Doxorubicin
Drug: 6-Mercaptopurine
Drug: Etoposide
Drug: Fludarabine Phosphate
Drug: Prednisolone
Drug: Ifosfamide
Drug: Tioguanin
Drug: Pegaspargase
Drug: Methotrexate
Drug: Erwinase
Drug: Vincristine
Drug: Vindesine

First Posted Date: 2018-08-22

Last Posted Date: 2023-11-29

Lead Sponsor: Martin Schrappe

Target Recruit Count: 5000

Registration Number: NCT03643276

Locations: 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹
A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Phase 2

Recruiting

Conditions: Diffuse Sclerosis Systemic
Interstitial Lung Disease
Pulmonary Hypertension
Systemic Sclerosis

Interventions: Drug: Cyclophosphamide
Drug: Mesna
Drug: Rituximab
Drug: Alemtuzumab
Drug: Thiotepa
Drug: GM-CSF
Drug: Intravenous immunoglobulin
Radiation: Total Body Irradiation
Drug: Anti Thymocyte Globulin

First Posted Date: 2018-08-14

Last Posted Date: 2024-08-09

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 8

Registration Number: NCT03630211

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

Phase 1

Recruiting

Conditions: Aplastic Anemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Mantle Cell Lymphoma
Plasma Cell Myeloma
Chronic Lymphocytic Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Bone Marrow Failure
Follicular Lymphoma
Hodgkin Lymphoma

Interventions: Biological: Anti-Thymocyte Globulin
Drug: Cyclophosphamide
Biological: Cytokine-treated Veto Cells
Drug: Fludarabine
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2018-08-09

Last Posted Date: 2024-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT03622788

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy